VONVENDI (von willebrand factor, recombinant)

OFFICE ADMINISTRATION

FDA Approved Indications:
  • Indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease
Patients must meet the following criteria for the indications above:
  • Confirmed diagnosis of von Willebrand disease requiring on-demand treatment to control bleeding episodes, AND
  • Patient is at least 18 years old, AND
  • Patient does not have known hypersensitivity to mouse or hamster proteins
Dosing:
  • For each bleeding episode, administer the first dose of Vonvendi with an approved recombinant (non-von Willebrand factor containing) factor VIII [Antihemophilic factor (Recombinant)] if factor VIII baseline levels are below 40% or are unknown.
  • Initial dose of Vonvedi is 40-80 IU per kg.  Adjust dosage based on the extent and location of bleeding
  • If recombinant factor VIII is required, give recombinant factor VIII within 10 minutes of completing Vonvendi infusion at a ration of 1:3:1
  • Administer Vonvendi within 3 hours after reconstitution
Approval:
  • One year
Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone